Published By: Syndicate Market Research
Epidermal Growth Factor Receptor (EGFR) Antibodies
Market - Global Industry Perspective, Comprehensive
Forecast, 2015 – 2021
3422 SW 15 Street, Suit #8138,
Florida 33442, USA
Toll Free: 1-855-465-4651
Epidermal Growth Factor Receptor (EGFR) Antibodies Market
EGFR is the primary receptor recognized in a group of receptors and is a cell surface protein that binds to
epidermal growth factor. EGFR is a cell membrane growth factor receptor characterized by tyrosine kinase
receptor which plays very important role in the control of key cellular transduction pathways in both normal and
cancerous cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been
developed in cancer therapy.
On the basis of types, the global epidermal growth factor receptor (EGFR) antibodies market is segmented
into cetuximab, panitumumab, and nimotuzumab. Cetuximab and panitumumab are the most favored EGFR
antibodies which are utilized for treatment of cancer. Nimotuzumab is a humanized monoclonal antibody that
recognizes the EGFR antibody. These antibodies are used in the treatment of colorectal tumor as single
chairmen and in mix with routine chemotherapy.
Browse the full "Epidermal Growth Factor Receptor (EGFR) Antibodies Market - Global Industry
Perspective, Comprehensive Analysis and Forecast, 2015 – 2021" report
The report covers forecast and analysis for the epidermal growth factor receptor (EGFR) antibodies market on
a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021
based on revenue (USD Million). The report also offers detailed competitive landscape of the...